Q9997 HCPCS Level II code: Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Q9997 is the HCPCS code for “Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Short description: Ustekinumab-ttwe iv inj 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q9997 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2025
Where Q9997 sits
- 1Q codesTemporary codes
- 2Active code Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q9997 mean?
Q9997 is the HCPCS code for “Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q9997?
CMS lists Q9997’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9997
All Q codesQ9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mgQ9992Injection, buprenorphine extended-release (sublocade), greater than 100 mgQ9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgQ9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachQ9995Injection, emicizumab-kxwh, 0.5 mgQ9996Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mgQ9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mgQ9999Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg